China HIV Drugs Market Analysis Report 2022 to 2030

China HIV Drugs Market Analysis

$ 3999

China HIV Drugs Market is at around $2.55 Bn in 2023 and is projected to reach $3.61 Bn in 2030, exhibiting a CAGR of 5.1% during the forecast period. Increasing HIV/ AIDS prevalence, healthcare infrastructure improvement and new drug approvals and developments are all driving market expansion. The market is dominated by key players like Sinopharm, Jiangsu Hengrui Medicine, Shanghai Fosun Pharmaceuticals, ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, and AbbVie Inc.

ID: IN10CNPH011 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Aneri Parekh

Buy Now

China HIV Drugs Market Executive Summary

China HIV Drugs Market is at around $2.55 Bn in 2023 and is projected to reach $3.61 Bn in 2030, exhibiting a CAGR of 5.1% during the forecast period.

The drugs targeted to treat HIV/ AIDS in the Chinese healthcare system are the main focus of the HIV drug market in China. Antiretroviral medications, including combination therapy, are available in this market. Their goals are to suppress the virus and enhance patients' quality of life. The healthcare infrastructure, governmental policies, and the incidence of HIV/ AIDS all have an impact on the market's growth.

The Chinese HIV medicine industry is expanding steadily, owing to increased awareness, government initiatives, and improved access to treatment. The market is very competitive, with domestic and multinational pharmaceutical companies contending for market share. With a huge population living with HIV/ AIDS and ongoing attempts to improve healthcare coverage, the market is likely to expand further in the future years.

The HIV medicine industry has expanded significantly, with a projected value of $31.7 Bn in 2023. This expansion is driven by an increase in HIV diagnoses. However, the market landscape is changing as more generic alternatives become available, resulting in increased competition. To continue forward, financial barriers to treatment must be addressed, HIV stigma should be reduced, and support programs are needed to improve therapy accessibility in developing countries.

Sinopharm is a key player in China's HIV medicine business, accounting for a sizable portion of antiretroviral (ARV) drug distribution and retail sales. The company has a statewide distribution network that serves all provinces and regions in China. Sinopharm also operates a wide network of retail pharmacies that sell ARV medications directly to patients. Sinopharm has also collaborated with the government and other stakeholders to increase HIV medicine access in China.

China HIV drugs market

Market Dynamics

Market Growth Drivers:

Increasing HIV/ AIDS prevalence: The number of persons living with HIV/ AIDS in China has been gradually increasing, pushing up demand for antiretroviral therapy (ART) medications to treat the disease.

New Drug Approvals and Innovations The development of new and more effective HIV medications, as well as advances in drug delivery systems, has increased the number of treatment alternatives available in the Chinese market, boosting growth.

Healthcare Infrastructure Development: China has made significant investments in its healthcare infrastructure, including the development of facilities and the training of healthcare workers. This contributes to increased access to HIV/ AIDS treatment and care services throughout the country.

Market Restraints:

Regulatory Hurdles: Strict restrictions and lengthy approval processes for new pharmaceuticals may hinder industry expansion.

Stigma and Discrimination: Despite attempts to promote awareness and reduce the stigma surrounding HIV/ AIDS, prejudice against those living with the disease can impede access to treatment and healthcare.

Affordability and Access: While the Chinese government has made attempts to enhance access to HIV treatments, the high cost of some medications remains a barrier for many patients, particularly those from low-income families.

Healthcare Policies and Regulatory Landscape

The National Medical Products Administration (NMPA), which reports to China's State Council, is the authority office in charge of drug regulation. It is operated by the State Administration for Market Regulation. The applicant sends a New Drug Application (NDA) to the NMPA. Following its evaluation of the NDA, the NMPA inspects the applicant's production facilities on-site. The NMPA reserves the right to inquire about additional clinical data or other pertinent information from applicants. Regulations governing the NMPA are frequently updated, demanding continual monitoring and adjustment.

Competitive Landscape

Key Players:

Sinopharm
Jiangsu Hengrui Medicine
Shanghai Fosun Pharmaceuticals
ViiV Healthcare
Gilead Sciences
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Merck & Co.
Bristol-Myers Squibb
AbbVie Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Drugs Market Segmentation

By Drug Class

Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.